PANTHERx® Specialty Pharmacy (PANTHERx®), THE Rare Disease Specialty Pharmacy®, announced that it has been selected by Ultragenyx Pharmaceutical, Inc. to distribute Crysvita™ (burosumab-twza), the very first FDA-approved therapy for children …
PANTHERx® Specialty Pharmacy is honored to announce our sponsorship of the Soft Bones International Scientific Meeting to promote education and advocacy for hypophosphatasia (HPP). This meeting will host the thought …
Gene therapy isn’t on the horizon anymore; it’s here. Precision medicine demands a level of personalization that few Specialty Pharmacies are equipped to handle. PANTHERx®’s pure focus on rare and …
PANTHERx® Specialty Pharmacy is pleased to announce that it has received full reaccreditation from URAC, pursuant to Specialty Pharmacy, Version 3.0. This accreditation is a reflection of PANTHERx®’s unwavering commitment …
PANTHERx® Specialty Pharmacy, The Rare Disease SP®, is honored to be the recipient of the 2018 APPA “Specialty Pharmacy of the Year Award” and Chairman & CEO, Dr. Gordon J. …
PANTHERx® Specialty Pharmacy (PANTHERx®), THE Rare Disease Specialty Pharmacy®, announced that it has been selected by Otsuka America Pharmaceutical, Inc. (Otsuka) to distribute JYNARQUE™ (tolvaptan), the only FDA-approved therapy for …
PANTHERx® Specialty Pharmacy, THE Rare Disease Specialty Pharmacy®, has been named the winner of the Specialty Pharmacy Patient Choice Award™ for the non-PBM/payer category. This is the second consecutive year …
PANTHERx® Specialty Pharmacy, The Rare Disease SP®, has once again earned the #1 ranking in the quarterly Patient Satisfaction Survey from Zitter Health Insights for the fourth quarter of 2017. …
PANTHERx® Specialty Pharmacy’s Fellowship program was featured in an article published by Specialty Pharmacy Continuum on April 11, 2018. The fellowship is designed to help address an emerging need in …
